FY2024 EPS Estimates for MIRM Increased by Leerink Partnrs

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for Mirum Pharmaceuticals in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($1.60) for the year, up from their prior forecast of ($1.63). The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.45) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals' Q4 2024 earnings at ($0.24) EPS and FY2025 earnings at ($0.83) EPS.

Several other research firms have also recently commented on MIRM. Leerink Partners lifted their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. Citigroup boosted their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Finally, HC Wainwright reiterated a "buy" rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $57.10.

Mirum Pharmaceuticals Stock Down 2.3 %

Mirum Pharmaceuticals stock traded down $1.12 during midday trading on Friday, hitting $47.53. 435,624 shares of the stock were exchanged, compared to its average volume of 489,048. Mirum Pharmaceuticals has a 52-week low of $23.14 and a 52-week high of $49.27. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The business's 50-day moving average price is $43.70 and its 200-day moving average price is $41.45. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -23.53 and a beta of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to analysts' expectations of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business's revenue was up 89.4% on a year-over-year basis. During the same period last year, the business earned ($0.57) EPS.

Insiders Place Their Bets

In related news, COO Peter Radovich sold 1,998 shares of the company's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $85,554.36. Following the sale, the chief operating officer now directly owns 27,015 shares in the company, valued at approximately $1,156,782.30. This represents a 6.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Jolanda Howe sold 2,500 shares of the firm's stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00. Following the completion of the transaction, the senior vice president now directly owns 2,426 shares of the company's stock, valued at approximately $114,264.60. This trade represents a 50.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 19,706 shares of company stock worth $875,697 over the last quarter. 22.87% of the stock is currently owned by company insiders.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Golden State Equity Partners grew its holdings in Mirum Pharmaceuticals by 1,390.8% during the 4th quarter. Golden State Equity Partners now owns 19,380 shares of the company's stock valued at $801,000 after buying an additional 18,080 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Mirum Pharmaceuticals by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company's stock valued at $421,000 after acquiring an additional 1,003 shares during the period. R Squared Ltd purchased a new position in Mirum Pharmaceuticals during the fourth quarter valued at approximately $69,000. Secure Asset Management LLC increased its holdings in Mirum Pharmaceuticals by 9.3% during the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company's stock worth $1,651,000 after acquiring an additional 3,406 shares during the period. Finally, Avanza Fonder AB purchased a new stake in Mirum Pharmaceuticals in the 4th quarter worth approximately $189,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.